P.A. Merle

View Scopus Profile

Research activity per year

If you made any changes in Pure these will be visible here soon.

5 Article
1 Meeting Abstract

A novel cryptic CBFB-MYH11 gene fusion present at birth leading to acute myeloid leukemia and allowing molecular monitoring for minimal residual disease
Poddighe, P. J., Veening, M. A., Mansur, M. B., Loonen, A. H., Westers, T. M., Merle, P. A., Wessels, J. W., de Haas, V., Kors, W. A., Bhola, S. L., Wondergem, M. J., Ford, A. M. & Kaspers, G. J. L., 1 Mar 2018, In: Human Pathology: Case Reports. 11, p. 34-38 5 p.
Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)
Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid
Verhagen, H. J. M. P., Smit, M. A., Rutten, A., Denkers, F., Poddighe, P. J., Merle, P. A., Ossenkoppele, G. J. & Smit, L., 28 Jan 2016, In: Blood. 127, 4, p. 458-463
Research output: Contribution to journal › Article › Academic › peer-review

34 Citations (Scopus)
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
White, H., Deprez, L., Corbisier, P., Hall, V., Lin, F., Mazoua, S., Trapmann, S., Aggerholm, A., Andrikovics, H., Akiki, S., Barbany, G., Boeckx, N., Bench, A., Catherwood, M., Cayuela, J. M., Chudleigh, S., Clench, T., Colomer, D., Daraio, F., Dulucq, S., & 51 othersFarrugia, J., Fletcher, L., Foroni, L., Ganderton, R., Gerrard, G., Gineikiene, E., Hayette, S., El Housni, H., Izzo, B., Jansson, M., Johnels, P., Jurcek, T., Kairisto, V., Kizilors, A., Kim, D. W., Lange, T., Lion, T., Polakova, K. M., Martinelli, G., McCarron, S., Merle, P. A., Milner, B., Mitterbauer-Hohendanner, G., Nagar, M., Nickless, G., Nomdedeu, J., Nymoen, D. A., Leibundgut, E. O., Ozbek, U., Pajic, T., Pfeifer, H., Preudhomme, C., Raudsepp, K., Romeo, G., Sacha, T., Talmaci, R., Touloumenidou, T., van der Velden, V. H. J., Waits, P., Wang, L., Wilkinson, E., Wilson, G., Wren, D., Zadro, R., Ziermann, J., Zoi, K., Mueller, M. C., Hochhaus, A., Schimmel, H., Cross, N. C. P. & Emons, H., 2015, In: Leukemia. 29, 2, p. 369-376
Research output: Contribution to journal › Article › Academic › peer-review

67 Citations (Scopus)
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment
Janssen, J. J. W. M., Berendse, H. W., Schuurhuis, G. J., Merle, P. A. & Ossenkoppele, G. J., 2009, In: American journal of hematology. 84, 10, p. 679-682
Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)
Immunophenotypical minimal residual disease as a short term endpoint for monitoring effects of targeted inhibitors in acute myeloid leukemia.
Hess, CJ., Feller, N., Denkers, F., Merle, PA., Ossenkoppele, GJ., Waisfisz, Q. & Schuurhuis, GJ., 16 Nov 2005, In: Blood. 106, 11, p. 162A-162A
Research output: Contribution to journal › Meeting Abstract › Academic

P.A. Merle

Research output

A novel cryptic CBFB-MYH11 gene fusion present at birth leading to acute myeloid leukemia and allowing molecular monitoring for minimal residual disease

Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR

A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment

Immunophenotypical minimal residual disease as a short term endpoint for monitoring effects of targeted inhibitors in acute myeloid leukemia.